Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Roche, Genentech File sBLA for Avastin to Treat NSCLC | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Roche, Genentech File sBLA for Avastin to Treat NSCLC

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Roche and Genentech have filed an sBLA for Avastin in the U.S. for the treatment of non-squamous, non-small cell lung cancer (NSCLC). The sBLA has been submitted for use of Avastin in combination with a platinum-based chemotherapy for previously untreated patients suffering from advanced NSCLC, which accounts for 87% of all lung cancers cases.

The sBLA submission is based on Genentech’s results of the E4599 trial that enrolled 878 patients with locally advanced, metastatic or recurrent NSCLC with histology other than predominant squamous cell. The results showed that patients receiving Avastin at a dose of 15mg/kg every three weeks plus paclitaxel and carboplatin had a 25% improvement in overall survival. The trial’s primary endpoint compared to patients who received chemotherapy alone, is equivalent to a 20% reduction in the risk of death. The survival of patients treated with Avastin plus chemotherapy was 12.3 months, compared to 10.3 months for patients treated with chemotherapy alone.

The study also showed a 54% improvement in progression-free survival, which can also be referred to as a 35% reduction in the risk of progression. The response rate in patients with measurable disease was 29% in the group receiving Avastin plus chemotherapy, compared to 13% in the group receiving chemotherapy alone. Pulmonary hemorrhage cases were observed in 2.3% of the patients receiving Avastin plus chemotherapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters